Robert J. Adelman

Innovative Spinal Technologies, Inc. (IST) develops spinal technology products and surgical protocols. Its products include Axient, Paramount PSS, Paramount VBR, and Cordant ACP. The company was founded in 2002 by Stephen Hochschuler and Barton Sachs and is headquartered in Mansfield, MA.

venBio Partners LLC (venBio) is a venture capital subsidiary of Venbio Partners LP founded in 2009 by Adelman robert and Goodman corey. The firm is headquartered in San Francisco, California.

Sorrento Tech, Inc., also known as Roka Bio Science, is a private company that specializes in food safety technology. The company is based in Warren, NJ and has subsidiaries in the United States. The company's core technology is the Roka pathogen detection assays, which combine the power of target capture, transcription-mediated amplification, and hybridization protection assay to deliver a fully automated, single-protocol assay with reduced enrichment times and superior sensitivity. The company's products include the Atlas® system and various detection assays for E. coli, Listeria, Salmonella, Campylobacter, and Legionella. Roka Bio Science provides solutions for the beef, dairy, pet food, poultry, produce, ready-to-eat foods, spices and ingredients, and environmental testing industries. Roka Bio Science was founded in 2009 by Paul G. Thomas.

Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA.

Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH.

Mirna Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of microRNA-based oncology therapeutics. Its products includes miR-34, miR-215, miR-101, miR-16, and let-7. The company was founded Matthew M. Winkler in 2007 and is headquartered in Austin, TX.

Aragon Pharmaceuticals, Inc. develops biopharmaceutical products, It offers a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers. The company was founded by Charles L. Sawyers and Michael Jung on May 1, 2009 and is headquartered in San Diego, CA.

Labrys Biologics, Inc. provides biotechnology services. It is a venture-financed development stage biotechnology company, which focuses on treatments for chronic migraine. The company was founded by Corey S. Goodman in 2012 and is headquartered in San Francisco, CA.

Solstice Biologics LLC develops nucleic acid therapeutics. It specializes in the development of small, cell-permeable RNAi pro-drugs. The company was founded by Steven Dowdy and Curt W. Bradshaw in 2012 and is headquartered in San Diego, CA.

Seragon Pharmaceuticals, Inc. developes biopharmaceutical products for the treatment of estrogen receptor dependent breast cancer. The company was founded in 2013 and is headquartered in San Diego, CA.

Heart Metabolics Ltd. operates as a biopharmaceutical company that engages in developing new treatments for orphan disease including cardio-metabolic diseases. The firm provides drugs to treat heart failure for hypertrophic cardiomyopathy patients. The company was founded by Michael Paul Frenneaux and Houshman Ashrafian in 2004 and is headquartered in Dublin, Ireland.

Veritas Medicine, Inc. operates an online database of clinical trials. It offers patient enrollment solutions to determine eligibility for upcoming clinical trials. The company was founded by Robert Adelman, Joshua Schultz, and Stephen Knight in 1999 and is headquartered in Cambridge, MA.

Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.

Part of ALX Oncology Holdings, Inc., ALX Oncology, Inc. operates as a clinical-stage immuno-oncology company which develops therapies for cancers. The company is based in Burlingame, CA. The CEO of the company is Jaume Pons.